Working... Menu

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Compare the Safety and Immunogenicity of Recombinant Envelope Protein rgp120/HIV-1SF2 (BIOCINE) Combined With Seven Adjuvants in Healthy HIV-1 Uninfected Individuals

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00001042
Recruitment Status : Completed
First Posted : August 31, 2001
Last Update Posted : May 23, 2012
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)